• Explore /
  • Poster
  • / Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 Japanese subgroup analysis.

Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 Japanese subgroup analysis.

Abstract Poster

Authors

null

Norihiko Tsuchiya

Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan

Norihiko Tsuchiya , Yoshiaki Yamamoto , Hirotsugu Uemura , Hiro-Omi Kanayama , Masatoshi Eto , Hideaki Miyake , Thomas Powles , Mizuki Yoshida , Yuichiro Koide , Yoshiko Umeyama , Alessandra Di Pietro , Yoshihiko Tomita

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02603432

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 425)

DOI

10.1200/JCO.2021.39.6_suppl.425

Abstract #

425

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Srikala S. Sridhar

First Author: Masatoshi Eto

First Author: Thomas Powles

First Author: Philippe Barthelemy